EGFR and head and neck squamous cell carcinoma: Van Dijk et al. [11, 37] demonstrated in a murine model of head and neck squamous cell carcinoma that 111In-F(ab′)2-cetuximab showed good tumor-to-background contrast on microSPECT imaging, allowing noninvasive assessment of EGFR expression in vivo.